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Genetic Variants in Fanconi Anemia Pathway Genes
BRCA2 and FANCA Predict Melanoma Survival
Jieyun Yin1,2,7, Hongliang Liu1,7, Zhensheng Liu1, Li-E Wang3, Wei V. Chen4, Dakai Zhu5,
Christopher I. Amos5, Shenying Fang6, Jeffrey E. Lee6 and Qingyi Wei1
Cutaneous melanoma (CM) is the most lethal skin cancer. The Fanconi anemia (FA) pathway involved in DNA
crosslink repair may affect CM susceptibility and prognosis. Using data derived from published genome-wide
association study, we comprehensively analyzed the associations of 2,339 common single-nucleotide polymorph-
isms (SNPs) in 14 autosomal FA genes with overall survival (OS) in 858 CM patients. By performing false-positive
report probability corrections and stepwise Cox proportional hazards regression analyses, we identified
significant associations between CM OS and four putatively functional SNPs: BRCA2 rs10492396 (AG vs. GG:
adjusted hazard ratio (adjHR)¼ 1.85, 95% confidence interval (CI)¼ 1.16–2.95, P¼ 0.010), rs206118 (CC vs. TTþ TC:
adjHR¼ 2.44, 95% CI¼ 1.27–4.67, P¼ 0.007), rs3752447 (CC vs. TTþ TC: adjHR¼ 2.10, 95% CI¼ 1.38–3.18, P¼ 0.0005),
and FANCA rs62068372 (TT vs. CCþCT: adjHR¼ 1.85, 95% CI¼ 1.27–2.69, P¼ 0.001). Moreover, patients with an
increasing number of unfavorable genotypes (NUG) of these loci had markedly reduced OS and melanoma-
specific survival (MSS). The final model incorporating with NUG, tumor stage, and Breslow thickness showed an
improved discriminatory ability to classify both 5-year OS and 5-year MSS. Additional investigations, preferably
prospective studies, are needed to validate our findings.
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INTRODUCTION
In contrast to the stable or declining trends for most cancer
types, the incidence of cutaneous melanoma (CM) is increas-
ing in the United States (Siegel et al., 2014), where B76,100
CM and additional 63,770 in situ cases are expected to occur
with 9,710 deaths in 2014 (Siegel et al., 2014). This increase
can be partly ascribed to increasingly sensitive and effective
screening, as reflected by the decreasing mean tumor
thickness (Lens and Dawes, 2004); nevertheless, there has
been little improvement in accurately assessing patient
prognosis, because CM still has a heterogeneous prognosis,
and the overall 5-year CM survival rate varies substantially
among patients, from 15% for distant metastasis toB98% for
localized CM (Balch et al., 2009).
Current prognostic tools mainly included clinicopathologi-
cal variables, such as tumor stage and Breslow thickness
(Balch et al., 2009). However, these methods have insufficient
discriminative ability for personalized clinical assessment
(Schramm and Mann, 2011). For example, sentinel lymph
node biopsy has emerged as an effective and powerful strategy
for staging the regional lymphatics in intermediate-thickness
CM; yet, its prognostic role in thin CM remains somewhat
controversial (Sabel, 2012; Kupferman et al., 2014).
Meanwhile, it remains difficult to establish prognostic
models for CM patients with age o20 years (Sanlorenzo
et al., 2013). These call for development of additional or better
markers with specific prognostic potential, allowing for
personalized health care. There is growing evidence for a
role of genetic (germline) variants in CM prognosis (Liu et al.,
2012; Li et al., 2013; Rendleman et al., 2013), which may
lead to improved prediction of prognosis. Discovery of such
genetic variants might also provide clues about the
mechanisms underlying melanocyte carcinogenesis and CM
progression.
Fanconi anemia (FA) is an inherited disease associated with
bone marrow failure, progressive pancytopenia, and multiple
developmental defects and is characterized by chromosomal
instability, cancer susceptibility, and exquisite sensitivity to
agents that produce DNA interstrand cross-links. The FA
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pathway consists of at least 14 complementation groups
(i.e., FANCA, B, C, D1 (BRCA2), D2, E, F, G, I, J, L, M, N,
and P (BTBD12)) and one FA-like complementation group
(FANCO; Crossan and Patel, 2012). In brief, the eight
upstream FA proteins assemble into a core complex
(FANCA, B, C, E, F, G, L, and M), and then mono-
ubiquitylate its two substrates, FANCD2 and FANCI.
Consequently, the ubiquitinated FANCD2/FANCI complex is
directed to the nucleus where it binds to chromatin and
recruits the downstream FA proteins (FANCD1, N, and J) and
additional DNA repair proteins (i.e., BRCA1; Stoepker et al.,
2011; Crossan and Patel, 2012). These downstream members
participate in DNA repair by homologous recombination
(Moldovan and D’Andrea, 2009). The main role of FA
proteins is to repair DNA crosslinks (Kennedy and D’Andrea,
2005). In addition, the FA pathway can promote stem-cell
function, stabilize replication forks, prevent tumorigenesis,
and inhibit inaccurate repair (Kennedy and D’Andrea, 2005;
Kottemann and Smogorzewska, 2013).
Although UV light induces DNA lesions, disrupts genetic
integrity, and contributes to CM susceptibility (von Thaler
et al., 2010), the host DNA repair capacity may also affect
treatment efficacy and resistance to certain chemotherapeutic
regimens and thereby affect malignant progression and patient
survival (Munshi et al., 2005; Chin et al., 2006; Emmert and
Kraemer, 2013). For example, genetic variants of nucleotide
excision repair genes affect CM survival (Li et al., 2013). Here,
we hypothesize that genetic variations in the FA pathway
genes may also modulate clinical outcome of CM patients. In
the present study, we tested our hypothesis by using
genotyping data of single-nucleotide polymorphisms (SNPs)
in the FA pathway genes from a previously published genome-
wide association study (GWAS) of CM (Amos et al., 2011). We
evaluated associations of prognosis in non-Hispanic white CM
patients with common SNPs in 14 autosomal genes, with one
exception for FANCB that is located in X chromosome.
RESULTS
Patient characteristics
As previously described, this study included 858 patients with
primary CM (Supplementary Table S1 online), who had
complete information about clinical variables, questionnaire
data, and GWAS data (Li et al., 2013). The patients were aged
between 17 and 94 years at diagnosis (52.4±14.4 years).
There were more stage I/II patients (709, 82.6%) than stage III/
IV patients (149, 17.4%). The patients had a median follow-up
time of 81.1 months, during which 133 (15.5%) had died for
any reasons at the last follow-up. Among these deaths, 95 died
of CM. In the multivariate analyses, six variables were found
to be independently and significantly associated with overall
survival (OS), including age at diagnosis, Clark level, tumor
stage, Breslow thickness, sentinel lymph node biopsy, and the
mitotic rate.
Multivariate analysis of SNPs and CM OS
To assess the associations of 321 genotyped and 2,018
imputed SNPs with OS (Supplementary Table S2 online), we
performed multivariate Cox proportional hazards regression.
As shown in Supplementary Figure S1, 138 SNPs were
individually significantly associated with OS at Po0.05 in
an additive model, of which 77 SNPs were still considered
noteworthy after the correction by the false-positive report
probability (FPRP) and 15 of these 77 SNPs were predicted to
be functional, on the basis of the in silico functional prediction
by using SNPinfo. These 15 SNPs included seven SNPs of
BRCA2, seven SNPs of FANCA, and one SNP of BTBD12
(Supplementary Table S3 online).
FA pathway variants as independent survival risk factors
Initial stepwise Cox proportional hazards regression analyses
suggested four SNPs (BRCA2 rs10492396 G4A, rs206118
T4C, and rs3752447 C4T and FANCA rs62068372 T4C) as
independent predictors for OS of CM patients (Table 1 and
Supplementary Table S3 online). In multivariate Cox propor-
tional hazards regression analyses using an additive model,
HR for rs206118 C was 1.40, whereas rs3752447 T and
rs62068372 C showed a protective effect against death
(Table 2). In codominant model, the rs10492396 (only one
subject with AA) heterozygous genotype showed a strong
association with a shorter OS (AG vs. GG: adjusted hazard
ratio (adjHR)¼1.85, 95% confidence interval (CI)¼1.16–
2.95, P¼0.010). Patients with rs206118 CC exhibited sig-
nificantly increased hazards of early death, compared with
those who had TTþTC genotypes (adjHR¼2.44, 95%
CI¼ 1.27–4.67, P¼ 0.007). In addition, the rs3752447 CC
genotype had a statistically significant impact on OS, com-
pared with TTþTC genotypes (adjHR¼2.10, 95% CI¼ 1.38–
3.18, P¼0.0005). Furthermore, rs62068372 was also asso-
ciated with unfavorable OS, with an HR of 1.85 (TT vs. CCþ
CT: 95% CI¼1.27–2.69, P¼ 0.001). For melanoma-specific
survival (MSS), rs3752447 CC or rs62068372 TT was more
likely to be associated with MSS, compared with other
genotypes (adjHR¼2.02 and 1.79, respectively), and
rs206118 CC was marginally associated with MSS
(adjHR¼2.12, P¼0.057, compared with CTþTT); however,
no significant association was observed between rs10492396
and MSS (Table 2). Supplementary Table S4 online showed the
correlation coefficients between these four SNPs, indicating that
the effects of SNPs are mostly independent.
Survival of melanoma patients with unfavorable genotypes
When we combined the risk genotypes of rs206118,
rs10492396, and rs3752447 in BRCA2 and rs62068372 in
FANCA into one variable as the number of unfavorable
genotypes (NUG), the frequencies of 0, 1, 2, and 3/4 NUG
were 116, 357, 322, and 62 (there was only one patient
carrying four NUGs), respectively. As illustrated in Table 3,
per-unit increase in NUG was associated with a reduced OS
(adjHR¼1.91, 95% CI¼ 1.53–2.39, Ptrendo0.0001) and MSS
(adjHR¼1.79, 95% CI¼1.38–2.31, Ptrendo0.0001), respec-
tively. Prognosis was worst in patients with 3/4 NUG for OS
(adjHR¼7.49; 95% CI¼ 3.36–16.70, Po0.0001) and for MSS
(adjHR¼4.65; 95% CI¼1.81–11.91, P¼0.001).
We next dichotomized all patients into a low-risk group
(with 0–1 NUG) and a high-risk group (with 2–4 NUG). We
found that compared with the low-risk group, the mortality in
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Table 2. Associations between survival of CM patients and selected SNPs in the FA pathway
Genotype No. of patients
OS MSS
Death (%)
Univariate analysis Multivariate analysis1
Death (%)
Univariate analysis Multivariate analysis1
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
BRCA2
rs10492396 (imputed)
GG 755 110 (14.6) 1.00 1.00 81 (10.7) 1.00 1.00
AG 102 23 (22.6) 1.55 (0.99–2.44) 0.055 1.85 (1.16–2.95) 0.010 14 (13.7) 1.31 (0.74–2.31) 0.349 1.52 (0.85–2.71) 0.158
AA 1
rs206118 (genotyped)
TT 583 88 (15.1) 1.00 1.00 61 (10.5) 1.00 1.00
TC 243 35 (14.4) 0.94 (0.64–1.39) 0.764 1.16 (0.77–1.75) 0.484 27 (11.1) 1.04 (0.66–1.64) 0.859 1.25 (0.77–2.02) 0.369
CC 32 10 (31.3) 2.30 (1.20–4.43) 0.013 2.53 (1.31–4.90) 0.006 7 (21.9) 2.29 (1.05–5.01) 0.038 2.26 (1.03–4.97) 0.043
Trend 1.21 (0.90–1.62) 0.208 1.40 (1.04–1.87) 0.027 1.27 (0.90–1.78) 0.177 1.39 (0.99–1.96) 0.058
CC vs. TTþ TC 2.34 (1.23–4.47) 0.001 2.44 (1.27–4.67) 0.007 2.26 (1.05–4.88) 0.038 2.12 (0.98–4.62) 0.057
rs3752447 (imputed)
CC 589 102 (17.3) 1.00 1.00 1.00 1.00
CT 243 29 (11.9) 0.63 (0.42–0.96) 0.030 0.49 (0.32–0.75) 0.001 72 (12.2) 0.70 (0.43–1.13) 0.141 0.53 (0.32–0.87) 0.011
TT 26 2 (7.7) 0.41 (0.10–1.66) 0.211 0.34 (0.08–1.39) 0.134 22 (9.1) 0.29 (0.04–2.12) 0.224 0.21 (0.03–1.52) 0.122
Trend 0.63 (0.44–0.92) 0.015 0.51 (0.35–0.75) 0.0006 1 (3.9) 0.66 (0.43–1.02) 0.059 0.51 (0.33–0.80) 0.003
CC vs. TTþCT 1.64 (1.09–2.45) 0.017 2.10 (1.38–3.18) 0.0005 1.52 (0.95–2.43) 0.082 2.02 (1.24–3.29) 0.005
FANCA
rs62068372 (imputed)
TT 467 84 (18.0) 1.00 1.00 59 (12.6) 1.00 1.00
CT 332 38 (11.5) 0.64 (0.44–0.95) 0.025 0.50 (0.33–0.75) 0.001 27 (8.1) 0.66 (0.42–1.04) 0.076 0.51 (0.31–0.82) 0.006
CC 59 11 (18.6) 1.10 (0.59–2.06) 0.765 0.73 (0.38–1.39) 0.336 9 (15.3) 1.26 (0.62–2.54) 0.520 0.81 (0.40–1.67) 0.575
Trend 0.84 (0.63–1.12) 0.229 0.68 (0.50–0.91) 0.011 0.90 (0.64–1.25) 0.515 0.71 (0.50–1.01) 0.058
TT vs. CCþCT 1.41 (0.99–2.00) 0.059 1.85 (1.27–2.69) 0.001 1.33 (0.88–2.02) 0.176 1.79 (1.15–2.77) 0.010
Abbreviations: CI, confidence interval; CM, cutaneous melanoma; FA, Fanconi anemia; HR, hazards ratio; MSS, melanoma-specific survival; OS, overall
survival; SLNB, sentinel lymph node biopsy; SNP, single-nucleotide polymorphism.
1Adjusted by age, sex, tumor stage, Breslow thickness, SLNB, Clark level, ulceration of tumor, and tumor cell mitotic rate in the Cox models.
Table 1. Predictors of OS in CM patients in stepwise Cox regression analysis of selected variables1
Parameter Category2 No. P-value HR 95% CI
Age 450/p50 487/371 o0.0001 1.05 1.03–1.06
Sex Female/male 361/496 0.009 0.59 0.40–0.87
Breslow thickness 44/1–4/p1 mm 68/443/347 o0.001 1.10 1.04–1.16
Tumor stage IIIþ IV/Iþ II 149/709 o0.0001 3.40 2.30–5.04
Clark level IVþV/IIþ III 459/399 0.009 1.85 1.17–2.92
Tumor cell mitotic rate X1/o1/mm2 583/275 0.040 1.75 1.03–2.99
Ulceration of tumor Yes/no 155/681 o0.0001 2.27 1.56–3.30
rs206118 CC/TTþ TC 32/826 0.017 2.24 1.16–4.32
rs10492396 AG/GG 102/755 0.011 1.85 1.16–2.97
rs3752447 CC/TTþ TC 589/269 o0.001 2.06 1.35–3.13
rs62068372 TT/CCþCT 467/391 0.002 1.81 1.24–2.63
Abbreviations: CI, confidence interval; CM, cutaneous melanoma; HR, hazards ratio; OS, overall survival; SLNB, sentinel lymph node biopsy.
1Age, sex, tumor stage, Breslow thickness, SLNB, Clark level, ulceration of tumor, tumor cell mitotic rate, and rs206118, rs15869, rs10492397, rs1207952,
rs10492396, rs17692629, rs3752447, rs8061528, rs62068372, rs56112321, rs34141697, rs8056353, rs56048434, rs62068387, and rs62068388 genotypes
were included in the stepwise multivariate Cox proportional hazard regression analysis.
2The ‘‘/category’’ was used as the reference.
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the high-risk group was more than 2-fold for either all causes
(adjHR¼2.41, 95% CI¼1.67–3.48, Po0.0001) or CM
(adjHR¼2.53, 95% CI¼1.65–3.89, Po0.0001). For illustra-
tive purpose, Kaplan–Meier curves of the associations with
OS, MSS, and NUG are shown in Figure 1.
Stratified analyses for NUG with CM survival
For stage-specific and thickness-specific associations between
NUG and CM survival (Table 4), we found that the high-risk
genotype group, but not the low-risk genotype group, showed
remarkably increased risk of death in those who had Breslow
thickness 41 mm, particularly for those with Breslow thick-
ness 44 mm. However, stratified analyses revealed that there
were no significant differences among strata of tumor stage
and thickness status (P for heterogeneity 40.100).
Receiver operating characteristic curve
Using multivariate logistic regression and receiver operating
characteristic curve, we further evaluated the NUG for its
potential to improve the classification of 5-year OS (N¼749;
133 died and 615 were alive) and 5-year MSS (N¼732; 95
died of CM). As shown in Figure 2, including only tumor stage
and Breslow thickness as classifiers, the 5-year OS model had
an area under the curve (AUC)¼73.7%; with the addition of
NUG, the AUC was significantly improved to 76.8%
(P¼ 0.001, DeLong’s test). With tumor stage and Breslow
thickness as classifier, the 5-year MSS had an AUC of 80.6%,
which improved to 82.8% after adding NUG (P¼0.025,
DeLong’s test). This suggests a potential role of the NUG in
prediction of patients at risk for death.
Bioinformatics analyses
By using the existing expression data in melanoma patients
from two studies from the public Gene Expression Omnibus
(GEO) database, who met the inclusion criterion, we then
examined the mRNA levels of BRCA2 and FANCA in GSE3189
(25 normal skin/nevi and 45 primary melanoma tissues) and
GSE8401 (31 primary melanoma and 52 melanoma metastasis
tissues). Figure 3 shows that BRCA2 had increased gene
expression levels in primary melanoma (Po0.0001,
GSE3189) and the metastasis (P¼0.014, GSE8401). Similar
results were found for FANCA (both Po0.001).
We further evaluated the correlations between SNPs and
their corresponding mRNA expression levels in normal cells,
using the published expression data of the HapMap normal
lymphoblastoid cell lines. Such expression data were available
for BRCA2 rs206118, rs10492396, and rs3752447. Consistent
with the observed associations, the rs3752447 CC genotype
was associated with significantly higher levels of mRNA
expression of BRCA2, compared with the TTþTC genotypes
(P¼ 0.040), whereas for rs10492396 the AG genotype carriers
had a marginally higher BRCA2 expression compared with
those with the GG genotype (no AA carrier; P¼ 0.073). No
significant correlation was found between rs206118 genotypes
and BRCA2 mRNA expression levels (P¼0.414) in a recessive
model. However, the BRCA2 mRNA expression levels
increased in a linear manner with the increasing number of
risk genotypes, when combining rs206118, rs10492396, and
rs3752447 (Ptrend¼0.019, Figure 4). We did not find any
significant result in an additive model (Supplementary Figure
S2 online), which supports our findings in the risk associations
that follow a recessive genetic model.
DISCUSSION
In the present study, we found that BRCA2 rs206118 T4C,
rs10492396 G4A, and rs3752447 C4T and FANCA
rs62068372 T4C were likely to independently or jointly
modulate survival of CM patients and that the incorporation
of numbers of risk genotypes of FANCA and BRCA2 could
significantly improve the prediction of CM OS and MSS. These
findings are biologically plausible, because FA proteins func-
tion at different steps in the sensing, recognition, and proces-
sing of DNA cross-links (Kottemann and Smogorzewska,
2013).
An activated FA pathway can provide resistance to
increased endogenous DNA damage and confer survival
Table 3. HRs for associations between survival and NUG across genes in the FA pathway in CM patients
NUG1
No. of
patients
OS MSS
Death (%)
Univariate
analysis
Multivariate
analysis2
Death (%)
Univariate
analysis
Multivariate
analysis2
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
0 116 10 (8.6) 1.00 1.00 8 (6.9) 1.00 1.00
1 357 46 (12.9) 1.55 (0.78–3.07) 0.208 2.02 (1.00–4.08) 0.050 33 (9.2) 1.37 (0.63–2.97) 0.425 1.57 (0.71–3.47) 0.268
2 322 59 (18.3) 2.28 (1.17–4.47) 0.016 3.63 (1.81–7.31) 0.0003 43 (13.4) 2.02 (0.95–4.30) 0.068 3.36 (1.54–7.35) 0.002
3/43 62 18 (29.0) 3.55 (1.64–7.69) 0.001 7.49 (3.36–16.70) o0.0001 11 (17.7) 2.66 (1.07–6.61) 0.035 4.65 (1.81–11.91) 0.001
Trend test P¼0.0001 Po0.0001 P¼ 0.007 Po0.0001
0–1 473 56 (11.8) 1.00 1.00 41 (8.7) 1.00 1.00
2–4 384 77 (20.1) 1.76 (1.25–2.49) 0.001 2.41 (1.67–3.48) o0.0001 54 (14.1) 1.66 (1.11–2.50) 0.014 2.53 (1.65–3.89) o0.0001
Abbreviations: CI, confidence interval; CM, cutaneous melanoma; FA, Fanconi anemia; HR, hazards ratio; MSS, melanoma-specific survival; NUG, number of
unfavorable genotypes; OS, overall survival; SLNB, sentinel lymph node biopsy.
1NUG included rs206118 CC, rs10492396 AG, rs3752447 CC, and rs62068372 TT.
2Adjusted by age, sex, tumor stage, Breslow thickness, SLNB, Clark level, ulceration of tumor, and tumor cell mitotic rate.
3Only one patient carrying four NUGs.
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advantage to melanoma cells (Nitta et al., 2010). Evidence
also exists that the FA pathway may also influence cancer
treatment and prognosis. For example, a 44-gene microarray-
based assay for the FA/BRCA pathway could discriminate two
different prognostic groups in breast cancer patients who were
treated with adjuvant 5-fluorouracil, epirubicin, and
cyclophosphamide (Mulligan et al., 2014). The absence of
the mouse Fancd2 gene product could confer radiosensitivity
to bone marrow stromal (Berhane et al., 2014). Although high
FANCD2 mRNA expression was a significant independent
factor for lymph node metastasis in colorectal cancer (Ozawa
et al., 2010), high FANCD2 protein expression appeared to be
prognostically unfavorable for OS of sporadic breast cancer
(van der Groep et al., 2008). Furthermore, high nuclear
staining for cytoplasmic FANCD2 appeared to be associated
with death in sporadic and metastatic human breast cancer
patients (Rudland et al., 2010); immunocytochemically, stain
of FANCD2 was associated with pathologic response to
neoadjuvant chemoradiation and OS in patients with
esophageal cancer (Alexander et al., 2012). Other FA genes
have also been shown to be associated with cancer outcomes.
For example, deletion/methylation of FANCC was significantly
associated with locoregional recurrence/death in patients with
head and neck squamous cell carcinoma in one study (Ghosh
et al., 2013) and was also associated with poor survival in
breast carcinoma in another study (Sinha et al., 2008).
Ovarian cancer cases with promoter methylation of FANCF
showed an increased risk of progression-free death, compared
with those without methylation (Lim et al., 2008). High
immunohistochemical expression of FANCJ was significantly
associated with 5-fluorouracil resistance and poor recurrence-
free survival in colorectal cancer (Nakanishi et al., 2012).
Finally, when restricted to lung cancer patients receiving
chemotherapy, the FANCE A250T variant could predict the
patients’ OS (Matakidou et al., 2007).
In the present study, we found some striking significant
associations of CM OS with genetic variants in FANCA and
BRCA2, although not all of these four SNPs showed a
significant association with CM MSS. However, the NUG of
these SNPs better predicted CM OS and MSS and discrimi-
nated among prognostic groups. Notably, the effect was
consistent across different analyses and multiple subgroup
comparisons, supporting a robust effect of the NUG on CM
survival, regardless of other pathological characteristics.
In the downloaded GEO dataset, we found that expression
of both FANCA and BRCA2 was upregulated in tumor tissues
of primary melanomas and melanoma metastases, suggesting
a possible contribution of FANCA and BRCA2 to CM progres-
sion. The BRCA2 (FANCD1) gene is located on 13q12.3,
whereas FANCA is mapped to 16q24.3. BRCA2 and FANCA
are the key members of the FA pathway. One study reported
that nine FA genes (including FANCA and BRCA2), but not
other DNA repair pathway genes, were transcriptionally
upregulated in melanoma tissues, compared with normal skin
and non-melanoma skin cancer (Kao et al., 2011). Although
few studies have linked FANCA and BRCA2 to CM prognosis,
100
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Figure 1. Kaplan–Meier survival analysis. For cutaneous melanoma (CM) overall survival (OS; a) by 0, 1, 2, and 3/4 number of unfavorable genotypes (NUG) (i.e.,
rs10492396 AG, rs206118 CC, rs3752447 CC, and rs62068372 TT) and (b) by 0–1 and 2–4 NUG; for CM MSS (c) by 0, 1, 2, and 3/4 NUG and (d) by 0–1 and
2–4 NUG.
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FANCA and BRCA2 have been shown to influence treatment
and prognosis in other cancers. For instance, recurrent
ovarian carcinomas commonly had increased BRCA2
protein expression post-chemotherapy exposure, which
could mediate resistance to platinum-based therapies
(Swisher et al., 2009), whereas the copy number of FANCA
might be correlated with poor prognosis of head and neck
cancer (Bauer et al., 2008). In addition, FANCA mRNA was
found to be upregulated in lung carcinoids with a poor
prognosis (Swarts et al., 2013).
Table 4. HRs for associations in stratified analyses between survival and NUG across genes in the FA pathway in CM
patients
NUG1 No. of patients
OS
Phet
MSS
Phet
Death (%) Log-rank P Multivariate analysis2 Death (%) Log-rank P Multivariate analysis2
HR (95% CI) P HR (95% CI) P
Tumor stage 0.0002 0.807 0.001 0.388
I/II
0–1 376 29 (7.7) 1.00 16 (4.3) 1.00
2–4 332 56 (16.9) 2.44 (1.53–3.90) 0.0002 35 (10.5) 3.12 (1.66–5.85) 0.0004
III/IV 0.097 0.135
0–1 97 27 (27.8) 1.00 25 (25.8) 1.00
2–4 52 21 (40.4) 2.21 (1.21–4.04) 0.010 19 (36.5) 2.02 (1.08–3.80) 0.029
Breslow
thickness (mm)
0.366 0.938
p1 0.978 0.806
0–1 187 10 (5.3) 1.00 4 (2.1) 1.00
2–4 160 9 (5.6) 1.32 (0.48–3.59) 0.589 3 (1.9) 2.36 (0.29–19.19) 0.422
41 and p4 0.0003 0.002
0–1 243 34 (14.0) 1.00 25 (10.3) 1.00
2–4 199 57 (28.6) 2.59 (1.65–4.06) o0.0001 42 (21.1) 2.66 (1.59–4.45) 0.0002
44 0.124 0.303
0–1 43 12 (27.9) 1.00 12 (27.9) 1.00
2–4 25 11 (44.0) 3.54 (1.28–9.82) 0.015 9 (36.0) 3.04 (1.01–9.14) 0.048
Abbreviations: CI, confidence interval; CM, cutaneous melanoma; FA, Fanconi anemia; HR, hazards ratio; OS, overall survival; MSS, melanoma-specific
survival; NUG, number of unfavorable genotypes; SLNB, sentinel lymph node biopsy.
Phet: P-values for heterogeneity.
1NUG included rs206118 CC, rs10492396 AG, rs3752447 CC, and rs62068372 TT.
2Adjusted by age, sex, tumor stage, Breslow thickness, SLNB, Clark level, ulceration of tumor, tumor cell mitotic rate.
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Figure 2. Receiver operating characteristic (ROC) curves for prediction of cutaneous melanoma (CM) survival. (a) Five-year overall survival (OS) rate and (b)
five-year melanoma-specific survival (MSS) rate, based on tumor stage and thickness, tumor stage, Breslow thickness plus NUG.
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Although rs206118, rs10492396, rs3752447, and
rs62068372 were predicted to affect corresponding gene
function by SNPinfo (Xu and Taylor, 2009), we were unable
to validate on our own specimens. In publically avai-
lable expression data of the 270 HapMap lymphoblastoid
cell lines derived from diverse populations (Holm et al., 2010),
we found that the BRCA2 mRNA expression levels related to
the NUG of rs206118, rs10492396, and rs3752447 of BRCA2.
This genotype–phenotype correlation provides biological evi-
dence that BRCA2 expression may be mediated jointly by
rs206118, rs10492396, and rs3752447, a possible explanation
for the observed association with CM survival.
A major strength of this study is the comprehensive analyses
of associations between SNPs in the FA pathway and CM
survival with a median follow-up time of 81.1 months. In our
analyses, we adjusted for some important variables that could
confound the genetic effect on OS. We also performed FPRP to
access the possibility of false-positive associations. Our find-
ings demonstrated the potential importance of assessing CM
prognosis by combining clinicopathological characteristics
with genetic information. The observed improvement of dis-
crimination of CM 5-year OS and MSS supports the prognostic
impact of associations and potential clinical applications.
However, the current study has some limitations. First, we
did not evaluate the potential effects of different therapies
on the outcomes of CM patients, or their potential associa-
tions with the identified SNPs, because patients received a
wide variety of systemic therapies, often sequentially, but
had relatively few outcome events for evaluation, making
the stratification not meaningful, if not unfeasible.
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However, the patients in the present study were recruited
before the time that vemurafenib was approved by the Food
and Drug Administration for the treatment of advanced
melanoma in 2011. Hence, the systemic therapies available
for the patients in our analysis could only have been
expected to be modestly effective in a minority of advanced
melanoma patients. We also performed stratified analyses
by tumor stage to minimize the effect of different treat-
ments. The results were consistent in stage I/II and stage III/
IV patients, suggesting that the presence of diverse treat-
ments might not have significant impact on CM in our
analysis, if any. Second, the prognosis predicting model was
only built in a non-Hispanic white population; the applica-
tion to other ethnic groups still needs further investigation.
Finally, because of the lack of validation in a similar patient
population, the interpretation of our findings should be
cautious, until validated by others.
MATERIALS AND METHODS
Study populations
Patients were accrued for a hospital-based case–control study of CM
at The University of Texas MD Anderson Cancer Center, and the
characteristics of these patients have also been described elsewhere
(Amos et al., 2011). Among the 1,804 patients, three were excluded
because of loss to follow-up after diagnosis. A total of 943 patients
were excluded because of missing questionnaire data that were not
collected at the clinic when the patients were seen. Therefore, the
final analysis included 858 patients who had complete information
for clinical prognostic variables (Supplementary Table S5 online).
Supplementary Figure S3 shows our sample selection strategy. All
individuals provided a written informed consent under an Institutional
Review Board-approved protocol.
SNP genotyping
The genotype data in this study can be accessed by using the
Database of Genotypes and Phenotypes (dbGaP; Mailman et al.,
2007), with study accession number phs000187.v1.p1. The detailed
genotyping information and data quality control can be found in the
previously described GWAS (Amos et al., 2011). Genome-wide
imputation was performed using the MACH software based on
1000 Genomes project, phase I V2 CEU data (Li et al., 2010).
SNP selection for the FA pathway analysis
On the basis of the databases of KEGG (http://www.genome.jp/kegg/)
and Biocarta (http://www.biocarta.com/), we selected the following 14
FA pathway genes that are located on autosomes: FANCA, FANCC,
BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, BRIP1, FANCL,
FANCM, PALB2, RAD51C, and BTBD12. Genotyped or imputed
common SNPs (minor allele frequency X0.05, genotyping rate
X95%, Hardy–Weinberg equilibrium P-valueX0.00001, and imputa-
tion r2X0.8) within these genes or their±20-kb flanking regions were
selected for association analysis. As a result, 321 genotyped SNPs and
2,018 imputed SNPs in the FA pathway were extracted from our CM
GWAS dataset (Supplementary Table S2 online).
FPRP
For all the significant results, we assigned a prior probability of 0.1 to
detect an HR of 2.0 for an association with genotypes and alleles of
each SNP (Wacholder et al., 2004). Only the signi-
ficant results with an FPRP value o0.2 were considered noteworthy.
Statistical methods
The OS time was calculated from the date of diagnosis to the date
of death from any cause or date of the last follow-up. MSS time was
determined from the time of diagnosis until death from CM;
individuals who died of causes other than CM were considered
to be censored. OS was the primary outcome measure to be
evaluated in the present study as we had a relatively enough
number of the events. First, associations between SNPs and OS (in
an additive model) were obtained by multivariable Cox propor-
tional hazards regression analyses performed with the GenABEL
package of R software (Aulchenko et al., 2007) with adjustment for
age, sex, tumor stage, Breslow thickness, sentinel lymph node
biopsy, Clark level, tumor cell mitotic rate, and ulceration of tumor
(Balch et al., 2009). We also applied a FPRP cutoff of 0.2 to limit
the probability of false-positive findings as a myriad of SNPs had
been tested. The significant and functional SNPs were identified by
using the FPRP correction and SNPinfo (Xu and Taylor, 2009) and
then were included with clinical prognostic variables into a
multivariable stepwise Cox proportional hazards regression
model. We summarized the number of risk genotypes identified
from the stepwise regression models for CM OS. Kaplan–Meier
survival curves and log-rank tests were used to evaluate the effects
of genetic variants on the cumulative probability of OS. Multiple
Cox proportional hazards regression models were also used for
stratified analyses by tumor Breslow thickness and stage. The
heterogeneity between subgroups was assessed with the w2-based
Q test, and the heterogeneity was considered significant when
Po0.100. Receiver operating characteristic curve was constructed
from the logistic regression model, and the AUC was used to assess
the classification performance of the model. Statistical significance
of the improvement in AUC after adding an explanatory factor was
calculated by Delong’s test (DeLong et al., 1988). Second, we also
investigated whether significant associations between the variants
and OS remained for MSS. Finally, to provide a biological context
for our findings, we searched the GEO database (http://
www.ncbi.nlm.nih.gov/geo/) for studies that provided mRNA
expression data from melanoma patients. The search terms were
‘‘melanoma’’ or ‘‘cutaneous melanoma’’ in combination with
‘‘human (organism)’’, limiting to sample sizes of more than 20.
Linear regression analysis was also used to test for the trends in the
associations between SNPs and corresponding gene expression
levels obtained from the 270 lymphoblastoid cell lines from CEU
and other HapMap samples (Holm et al., 2010). All other analyses
were performed using the SAS software (Version 9.3; SAS institute,
Cary, NC).
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